Browsing Tag
Atopic dermatitis
33 posts
Why Arcutis Biotherapeutics, Inc. is targeting infant eczema with ZORYVE cream
Can ZORYVE cream unlock infant eczema markets? Discover how Arcutis Biotherapeutics, Inc. is reshaping dermatology strategy today.
Aging biotech just got a real skin test and Rubedo Life Sciences may have passed the first one
Rubedo Life Sciences posted early RLS-1496 skin trial data. Read why these Phase 1 results could matter for dermatology, aging science, and biotech.
Can a new IL-13 drug quietly challenge Dupixent’s dominance in eczema treatment?
Apogee Therapeutics’ APEX data could reshape eczema treatment competition. Discover what it means for Dupixent, Ebglyss, and investors.
What rademikibart Phase 3 data could mean for Connect Biopharma’s immunology strategy (NASDAQ: CNTB)
Connect Biopharma’s rademikibart Phase 3 eczema data will debut at AAD 2026. Discover what it means for biologic competition and Connect Biopharma strategy.
What new Dupilumab data suggest about long-term immune control in allergic disease at Regeneron Pharmaceuticals
New Dupilumab analyses highlight immune modulation claims. Read how Regeneron Pharmaceuticals is testing durability, reimbursement logic, and long-term strategy.
Nektar Therapeutics (NASDAQ: NKTR) raises $460m as rezpegaldesleukin data strengthens Phase 3 autoimmune outlook
Nektar Therapeutics raised $460 million after strong rezpegaldesleukin data. Find out what this means for Phase 3 trials and autoimmune drug markets.
Why did Amgen Inc. walk away from its $1.25bn eczema drug deal with Kyowa Kirin?
Amgen Inc. exits its $1.25B eczema drug deal with Kyowa Kirin Co., Ltd., reshaping its immunology focus. Find out what this move means for both companies’ pipelines.
Sanofi bets on dosing discipline over rapid onset with amlitelimab’s Phase 3 readout
Sanofi moves amlitelimab toward global filings. Find out what the Phase 3 data mean for investors, competitors, and the dermatology biologics market.
What KT‑621 success could mean for oral immunology drugs and Kymera Therapeutics
Get ready for Kymera Therapeutics' KT‑621 Phase 1b data on December 8. Can this oral eczema drug change the future of immunology?
Simcere’s SIM0278 enters Phase II trial in China: Could IL-2 Treg fusion therapy transform atopic dermatitis care?
Simcere’s SIM0278 enters Phase II in China for atopic dermatitis. Explore how its IL-2 Treg selectivity could redefine treatment for autoimmune skin diseases.